Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Advanced glycation end products (AGE) accumulate in human tissue proteins during aging, particularly under hyperglycemia conditions. AGEs induce oxidative stress and inflammation via the receptor for AGEs (RAGE) and soluble RAGE (sRAGE) can neutralize the effects mediated by RAGE–ligand engagement. Methods: We examined the association between Nϵ-(carboxymethyl)lysine (CML), a prominent AGE, and sRAGE and colorectal cancer risk in a prospective case–cohort study nested within a cancer prevention trial among 29,133 Finnish male smokers. Among study subjects who were alive without cancer 5 years after baseline (1985–1988), we identified 483 incident colorectal cancer cases and randomly sampled 485 subcohort participants as the comparison group with the follow-up to April 2006. Baseline serum levels of CML-AGE, sRAGE, glucose and insulin were determined. Weighted Cox proportional hazard regression models were used to calculate relative risks (RR) and 95% CI. Results: Comparing highest with lowest quintile of sRAGE, the RR for incident colorectal cancer was 0.65 (95% CI, 0.39–1.07; Ptrend = 0.03), adjusting for age, years of smoking, body mass index, and CML-AGE. Further adjustment for serum glucose strengthened the association (RR = 0.52; 95% CI, 0.30–0.89; Ptrend = 0.009). Highest quintile of CML-AGE was not associated with an increased risk of colorectal cancer (multivariate RR = 1.20; 95% CI, 0.64–2.26). Conclusions: Higher prediagnostic levels of serum sRAGE were associated with lower risk of colorectal cancer in male smokers. Impact: This is the first epidemiologic study to implicate the receptor for AGEs in colorectal cancer development. Cancer Epidemiol Biomarkers Prev; 20(7); 1430–8. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“AGEs are a group of irreversible adducts or crosslinking created through a nonenzymatic glycosylation between reducing sugars and free amino groups of proteins, lipids, or nucleic acids (1).”
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
YONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Vlassara, H., Cai, W., Crandall, J., Goldberg, T., Oberstein, R., Dardaine, V., Peppa, M., & Rayfield, E. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242407999 · Cited by 668 · cited 1×
“Moreover, AGEs levels are modulated by dietary intake (43).”
Uribarri, J., Cai, W., Peppa, M., Goodman, S., Ferrucci, L., Striker, G., & Vlassara, H. (2007) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/62.4.427 · Cited by 570
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Cai, W., He, J. C., Zhu, L., Lu, C., & Vlassara, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600362103 · Cited by 163 · cited 1×
“receptor 1, that detoxify CML-AGE and counter-regulate their pro-oxidant effects (36).”
Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.007 · Cited by 148
Cited by
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
“One recent study has reported that individuals with the higher circulating levels of sRAGE had a lower risk of colorectal and hepatic cancer, although no association was found between sRAGE and pancreatic cancer in the EPIC cohort (68, 91, 140).”
BackgroundNew insights into pancreatic cancer-induced paraneoplastic diabetes
Sah, R. P., Nagpal, S. J. S., Mukhopadhyay, D., & Chari, S. T. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.49 · Cited by 334
Yang, Y., Zhao, L., Huang, B., Wang, R., Yuan, S., Tao, Q., Xu, Y., Sun, H., Lin, C., & Zhou, W. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22231 · Cited by 55
Papagrigoraki, A., Giglio, M., Cosma, C., Maurelli, M., Girolomoni, G., & Lapolla, A. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2661 · Cited by 46
Metadata
- Authors
- Jiao, L., Taylor, P. R., Weinstein, S. J., Graubard, B. I., Virtamo, J., Albanes, D., & Stolzenberg-Solomon, R. Z.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2011-07-01
- Volume
- 20
- Issue
- 7
- Pages
- 1430-1438
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2139355636
- Cited by
- 70
- References
- 9
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-11-0066
- The paper
- Jiao, L., Taylor, P. R., Weinstein, S. J., Graubard, B. I., Virtamo, J., Albanes, D., & Stolzenberg-Solomon, R. Z. (2011). Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-11-0066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.